Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology
Status:
Not yet recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to test the safety and tolerability of twice daily Verdiperstat
in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal
lobar degeneration with TDP-43 pathology (FTLD-TDP). Three-fourths of the participants will
receive Verdiperstat and one-fourth will receive Placebo during the 24-week treatment
duration.
Phase:
Phase 1
Details
Lead Sponsor:
Peter Ljubenkov, MD
Collaborators:
Alzheimer's Association National Institute on Aging (NIA) National Institutes of Health (NIH)